Edwards Lifesciences Corp
Company Stats
- Market Cap
- $49.8B
- as of Sep 30, 2026
- Shares Outstanding
- 576.4M
- Free Float
- 99.7%
Income Statement
- Revenue
- $6.1B
- Operating Income
- $1.3B
- Net Income
- $1.1B
- EBITDA
- $1.4B
- Non-cash Impairment
- $186.9M
- Revenue Growth, 3Y
- 10.8%
- FCF Margin, 3Y Avg
- 13.4%
- FCF Margin, Worst Year
- 5.3%
Cash Flow
- Free Cash Flow
- $1.3B
- FCF Yield
- 2.7%
- Owner FCF Yield
- 2.4%
Balance Sheet
- Cash & Equivalents
- $2.9B
Returns & Capital
- Share Repurchases
- $893.4M
- Buyback Yield, 3Y Avg
- 2.0%
- SBC, 3Y Avg
- $153.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $6.1B | $1.3B | 22.0% |
| FY2024 | $5.4B | $289.9M | 5.3% |
| FY2023 | $5.0B | $642.8M | 12.8% |
| FY2022 | $4.5B | $973.6M | 21.8% |
| FY2021 | $5.2B | $1.4B | 26.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 10, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back